TXMD TherapeuticsMD Inc.

1.45
+0.05  (+4%)
Previous Close 1.4
Open 1.45
52 Week Low 0.853
52 Week High 4.32
Market Cap $394,826,851
Shares 272,294,380
Float 245,536,854
Enterprise Value $522,589,377
Volume 3,199,029
Av. Daily Volume 4,020,591
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
TX-001HR: BIJUVA
Moderate to severe vasomotor symptoms (VMS)
PDUFA
PDUFA
FDA approval announced October 29, 2018.
Segesterone Acetate/ Ethinyl Estradiol
Contraception
Approved
Approved
FDA Approval announced August 10, 2018.
Yuvvexy - TX-004HR
Moderate-to-severe vaginal pain
Approved
Approved
CRL announced May 8, 2017. NDA resubmitted with approval announced May 30, 2018.

Latest News

  1. TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will participate in two upcoming virtual investor conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences.

    Details for the presentations include:

    Conference

    H.C. Wainwright & Co. 22nd Annual Global Investment Conference

    Date

    Monday, September 14, 2020

    Time

    3:00 p.m. Eastern time

    Conference

    Cantor Virtual Global Healthcare Conference

    Date

    Thursday, September 17, 2020

    Time

    9:00 a.m. Eastern time

    A live webcast and replay of each presentation can be accessed on the company's website, www.therapeuticsmd.com, on the Home Page or under the "Investors…

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will participate in two upcoming virtual investor conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences.

    Details for the presentations include:

    Conference

    H.C. Wainwright & Co. 22nd Annual Global Investment Conference

    Date

    Monday, September 14, 2020

    Time

    3:00 p.m. Eastern time

    Conference

    Cantor Virtual Global Healthcare Conference

    Date

    Thursday, September 17, 2020

    Time

    9:00 a.m. Eastern time

    A live webcast and replay of each presentation can be accessed on the company's website, www.therapeuticsmd.com, on the Home Page or under the "Investors & Media" section.

    About TherapeuticsMD

    TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

    Forward-Looking Statements

    This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD's objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company's ability to maintain or increase sales of its products; the company's ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company's current or future approved products or preclude the approval of the company's future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company's ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company's reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company's licensees to commercialize and distribute the company's products; the ability of the company's marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company's products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company's common stock and the concentration of power in its stock ownership. PDF copies of the company's historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.

    View Full Article Hide Full Article
  2. New patents expand U.S. patent protection for ANNOVERA

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced patent updates for ANNOVERA(segesterone acetate and ethinyl estradiol vaginal system), the first and only long-lasting, patient-controlled, procedure-free, reversible prescription contraceptive option for women. On September 8, 2020, the United States Patent and Trademark Office (USPTO) issued its second ANNOVERA patent (U.S. Patent No. 10,765,628) that can be listed in the U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In addition, based on recent communications from the USPTO, a third ANNOVERA patent…

    New patents expand U.S. patent protection for ANNOVERA

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced patent updates for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only long-lasting, patient-controlled, procedure-free, reversible prescription contraceptive option for women. On September 8, 2020, the United States Patent and Trademark Office (USPTO) issued its second ANNOVERA patent (U.S. Patent No. 10,765,628) that can be listed in the U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book). In addition, based on recent communications from the USPTO, a third ANNOVERA patent (U.S. Patent No. 10,780,047) is scheduled to be issued on September 22, 2020. These Orange Book eligible patents, which provide patent protection through 2039, cover ANNOVERA and its use for the labeled indication of preventing pregnancy in females of reproductive potential.

    "Before the issuance of the first Orange Book listable patent for ANNOVERA, the product was protected by FDA regulatory exclusivity through 2023 as a new chemical entity. These additional patents, which cover different aspects of ANNOVERA, provide independent layers of patent protection," said Robert Finizio, TherapeuticsMD Chief Executive Officer. "As part of our intellectual property strategy, we continue to fortify ANNOVERA's patent portfolio to provide lasting durability for our flagship product. ANNOVERA is a critical component of our drive towards EBITDA breakeven in 2021."

    For Full Prescribing Information, including BOXED WARNING, please visit www.annovera.com/pi.pdf.

    About TherapeuticsMD

    TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

    Forward-Looking Statements for TherapeuticsMD Inc.

    This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD's objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company's ability to maintain or increase sales of its products; the company's ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company's current or future approved products or preclude the approval of the company's future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company's ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company's reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company's licensees to commercialize and distribute the company's products; the ability of the company's marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company's products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company's common stock and the concentration of power in its stock ownership. PDF copies of the company's historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.

    View Full Article Hide Full Article
  3. MONTREAL and BOCA RATON, Fla, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD") announced today the approval of IMVEXXY® by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas1-4. IMVEXXY is an applicator-free, estradiol softgel vaginal capsule indicated for postmenopausal women who experience pain before, during or after sex. IMVEXXY (estradiol vaginal inserts) is marketed by TherapeuticsMD…

    MONTREAL and BOCA RATON, Fla, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD") announced today the approval of IMVEXXY® by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas1-4. IMVEXXY is an applicator-free, estradiol softgel vaginal capsule indicated for postmenopausal women who experience pain before, during or after sex. IMVEXXY (estradiol vaginal inserts) is marketed by TherapeuticsMD in the U.S. for the treatment of moderate to severe dyspareunia, a symptom of VVA, due to menopause.

    "IMVEXXY offers a new option for postmenopausal women to address their unmet medical needs and helps manage the suffering associated with a very bothersome and painful VVA symptom that significantly impacts quality of life," said Samira Sakhia, President and Chief Operating Officer of Knight Therapeutics.

    "The approval of IMVEXXY by Health Canada marks a significant new milestone for Knight and we could not be more pleased as they bring this new treatment option to women in Canada," said Robert Finizio, Chief Executive Officer of TherapeuticsMD. 

    Knight and TherapeuticsMD signed a licensing agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to IMVEXXY and BIJUVA® (estradiol and progesterone) capsules. Under the terms of the licensing agreement related to IMVEXXY in Canada, Knight will pay TherapeuticsMD a milestone fee for the regulatory approval in Canada of IMVEXXY, sales milestone fees based upon certain aggregate annual sales of IMVEXXY in Canada, and royalties based on aggregate annual sales of IMVEXXY in Canada. 

    About IMVEXXY

    IMVEXXY (estradiol vaginal inserts) was developed and approved in the U.S. for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

    IMVEXXY is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose; the 4 mcg represents the lowest U.S. Food and Drug Administration-approved dose of vaginal estradiol.

    Please see the Full IMVEXXY® Canadian Product Monograph available at https://www.gud-knight.com.

    Please see U.S. Full Prescribing Information for IMVEXXY, including BOXED WARNING for endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia, available at www.imvexxy.com/pi.pdf.

    Please see U.S. Full Prescribing Information for BIJUVA, including BOXED WARNING for cardiovascular disorders, breast cancer, endometrial cancer and probable dementia, available at https://www.bijuva.com/pi.pdf.

    About Knight Therapeutics Inc.

    Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

    Forward-Looking Statements for Knight Therapeutics Inc.

    This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2019 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

    About TherapeuticsMD, Inc.

    TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

    Forward-Looking Statements for TherapeuticsMD Inc.

    This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD's objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company's ability to maintain or increase sales of its products; the company's ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company's current or future approved products or preclude the approval of the company's future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company's ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company's reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company's licensees to commercialize and distribute the company's products; the ability of the company's marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company's products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company's common stock and the concentration of power in its stock ownership. PDF copies of the company's historical press releases and financial tables can be viewed and downloaded at its website: https://ir.therapeuticsmd.com/press-releases.

    References:

    1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. 

    2. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902. 

    3. Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. Clin MedInsights Reprod Health. 2014;8:23-30. 

    4. Chen L, Ng M, van der Vlugt TH, Price PH, Orencia A. Statistical considerations for the efficacy assessment of clinical studies of vulvar and vaginal atrophy. Ther Innov Regul Sci. 2010;44(5):581-588.



    CONTACT INFORMATION:

    Knight Therapeutics Inc.

    Samira Sakhia

    President and Chief Operating Officer

    T: 514-678-8930

    F: 514-481-4116



    www.gudknight.com 



    Arvind Utchanah

    Chief Financial Officer

    T. 514.484.4483 ext. 115

    F. 514.481.4116

    Email: 

    Website: www.gud-knight.com

    TherapeuticsMD

    Nichol Ochsner

    Vice President, Investor Relations

    561-961-1900, ext. 2088

    Primary Logo

    View Full Article Hide Full Article
  4. Knight Therapeutics Inc. (TSX:GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD") announced today the approval of IMVEXXY® by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas1-4. IMVEXXY is an applicator-free, estradiol softgel vaginal capsule indicated for postmenopausal women who experience pain before, during or after sex. IMVEXXY (estradiol vaginal inserts)is marketedby TherapeuticsMD in the U.S. for the treatment of moderate to severe dyspareunia…

    Knight Therapeutics Inc. (TSX:GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD") announced today the approval of IMVEXXY® by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas1-4. IMVEXXY is an applicator-free, estradiol softgel vaginal capsule indicated for postmenopausal women who experience pain before, during or after sex. IMVEXXY (estradiol vaginal inserts) is marketed by TherapeuticsMD in the U.S. for the treatment of moderate to severe dyspareunia, a symptom of VVA, due to menopause.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200825005037/en/

    "IMVEXXY offers a new option for postmenopausal women to address their unmet medical needs and helps manage the suffering associated with a very bothersome and painful VVA symptom that significantly impacts quality of life," said Samira Sakhia, President and Chief Operating Officer of Knight Therapeutics.

    "The approval of IMVEXXY by Health Canada marks a significant new milestone for Knight and we could not be more pleased as they bring this new treatment option to women in Canada," said Robert Finizio, Chief Executive Officer of TherapeuticsMD.

    Knight and TherapeuticsMD signed a licensing agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to IMVEXXY and BIJUVA® (estradiol and progesterone) capsules. Under the terms of the licensing agreement related to IMVEXXY in Canada, Knight will pay TherapeuticsMD a milestone fee for the regulatory approval in Canada of IMVEXXY, sales milestone fees based upon certain aggregate annual sales of IMVEXXY in Canada, and royalties based on aggregate annual sales of IMVEXXY in Canada.

    About IMVEXXY

    IMVEXXY (estradiol vaginal inserts) was developed and approved in the U.S. for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

    IMVEXXY is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose; the 4 mcg represents the lowest U.S. Food and Drug Administration-approved dose of vaginal estradiol.

    Please see the Full IMVEXXY® Canadian Product Monograph available at https://www.gud-knight.com.

    Please see U.S. Full Prescribing Information for IMVEXXY, including BOXED WARNING for endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia, available at www.imvexxy.com/pi.pdf.

    Please see U.S. Full Prescribing Information for BIJUVA, including BOXED WARNING for cardiovascular disorders, breast cancer, endometrial cancer and probable dementia, available at https://www.bijuva.com/pi.pdf.

    About Knight Therapeutics Inc.

    Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

    Forward-Looking Statements for Knight Therapeutics Inc. This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2019 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

    About TherapeuticsMD, Inc.

    TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

    Forward-Looking Statements for TherapeuticsMD Inc.

    This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD's objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company's ability to maintain or increase sales of its products; the company's ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefore; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company's current or future approved products or preclude the approval of the company's future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company's ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company's reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company's licensees to commercialize and distribute the company's products; the ability of the company's marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company's products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company's common stock and the concentration of power in its stock ownership. PDF copies of the company's historical press releases and financial tables can be viewed and downloaded at its website: https://ir.therapeuticsmd.com/press-releases.

    References:

    1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94.

    2. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902.

    3. Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. Clin MedInsights Reprod Health. 2014;8:23-30.

    4. Chen L, Ng M, van der Vlugt TH, Price PH, Orencia A. Statistical considerations for the efficacy assessment of clinical studies of vulvar and vaginal atrophy. Ther Innov Regul Sci. 2010;44(5):581-588.

    View Full Article Hide Full Article
  5. - 2Q20 total net product revenue of $10.7 million resilient despite COVID-19 pandemic -

    - ANNOVERA® prescriptions increased approximately 100% for the eight weeks ended July 24, 2020 over the previous eight week period-

    - IMVEXXY® new prescriptions increased 33% for the eight weeks ended July 24, 2020 over the previous eight week period-

    - Consumer campaign for ANNOVERA achieved over 3 million unique views in first 30 days -

    - Initial consumer marketing campaign for IMVEXXYto be launched in August -

    - Amended Sixth Street Partners revenue covenants to reflect impact of COVID-19 pandemic -

    - Conference call scheduled for 8:30 a.m. ET today -

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today…

    - 2Q20 total net product revenue of $10.7 million resilient despite COVID-19 pandemic -

    - ANNOVERA® prescriptions increased approximately 100% for the eight weeks ended July 24, 2020 over the previous eight week period-

    - IMVEXXY® new prescriptions increased 33% for the eight weeks ended July 24, 2020 over the previous eight week period-

    - Consumer campaign for ANNOVERA achieved over 3 million unique views in first 30 days -

    - Initial consumer marketing campaign for IMVEXXY to be launched in August -

    - Amended Sixth Street Partners revenue covenants to reflect impact of COVID-19 pandemic -

    - Conference call scheduled for 8:30 a.m. ET today -

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the second quarter ended June 30, 2020.

    "Our organization made significant progress in the second quarter while navigating the COVID-19 pandemic and its impact on our business," said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. "We delivered a strong quarter of operational execution during very unique circumstances, quickly reducing our operating expenses, reorienting our sales force, and addressing our credit facility future minimum net revenue covenants. These strategic and operational changes and our reshaped Board of Directors and management team are focused on driving revenue and achieving our goal of reaching EBITDA break even in 2021, which we believe will result in long-term shareholder value."

    Recent Updates

    • Prescription volume for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) for the eight weeks ended July 24, 2020 increased approximately 100% over the previous eight weeks (the time period most heavily impacted by COVID-19). ANNOVERA current prescription trend exceeds the product's pre-COVID-19 launch trajectory.
    • The Company initiated the direct-to-consumer marketing campaign for ANNOVERA on July 1, 2020. Digital metrics show that the "Unapologetically ANNOVERA" campaign has quickly gained visibility resulting in over 100 million impressions and 3 million unique views since launch.
    • The Company is working with the Department of Defense, public health organizations, and telehealth platforms to expand access to women and contribute to the Company's growth in the second half of the year.
    • As of July 1, 2020, ANNOVERA achieved 79% commercial coverage and 46% Medicaid coverage. The vast majority of patients are covered without a copay.
    • IMVEXXY (estradiol vaginal inserts) new prescriptions for the eight weeks ended July 24, 2020 increased 33% over the previous eight weeks ended May 29, 2020 (the time period most heavily impacted by COVID-19). IMVEXXY continues to experience strong refill rates. These trends should positively impact total prescriptions going forward.
    • The Company plans to launch the consumer marketing campaign for IMVEXXY during August 2020.
    • IMVEXXY's commercial market access is 72% unrestricted commercial coverage, including all of the top ten commercial payors of VVA products. The Company added Wellcare as a Medicare Part D payor.
    • As of July 1, 2020, BIJUVA® (estradiol and progesterone) capsules commercial market access increased to 73% unrestricted commercial coverage with nine of the top ten commercial payors.

    Sixth Street Update

    • The Company worked with Sixth Street Partners ("Sixth Street") to adjust the total minimum net revenue covenant in its financing agreement to reflect the impact of COVID-19. The covenants begin with the results for the fourth quarter of 2020.
    • The total minimum net revenue requirement for ANNOVERA, IMVEXXY, and BIJUVA was adjusted to $20 million for the fourth quarter of 2020. In 2021, the minimum net revenue covenant will be $25 million, $37.5 million, $47.5 million, and $57.5 million for the first, second, third, and fourth quarters, respectively. Given the Company's current rate of growth, the Company believes it is well positioned to meet or exceed these minimum covenants.
    • The Company and Sixth Street are not moving forward with the undrawn $50 million tranche under the financing agreement, which was designed to be drawn following the successful full commercial launch of ANNOVERA in the second quarter, due to the pause in the launch timing caused by the COVID-19 pandemic. There continues to be an active dialogue with Sixth Street regarding potential additional financing.

    Second Quarter Highlights

    • Net product revenue for the second quarter of 2020 was $10.7 million.
    • The COVID-19 pandemic had a significant impact on the Company's product revenue early in the second quarter of 2020. The Company's products returned to growth mid to late quarter. Notwithstanding COVID-19, the Company expects continued growth in the second half of 2020.
    • In the second quarter 2020, ANNOVERA net revenue was $1.8 million. Approximately 2,400 ANNOVERA prescriptions were dispensed. Net revenue per unit, calculated from sales to wholesalers and pharmacies, was $1,332.
    • In the second quarter 2020, IMVEXXY net revenue was $5.1 million. Approximately 118,000 IMVEXXY prescriptions were dispensed. Net revenue per unit was $41. Strong IMVEXXY refill rates continued with patients adhering to therapy.
    • In the second quarter 2020, BIJUVA net revenue was $1.4 million. Approximately 27,600 BIJUVA prescriptions were dispensed. Net revenue per unit was $45 for the second quarter of 2020.

    Net Product Revenue

     

     

    Three Months

    Ended

    June 30, 2020

     

    Three Months

    Ended

    June 30, 2019

     

    Three Months

    Ended

    March 31, 2020

     

    ANNOVERA

     

    $

    1,835,460

     

    $

     

    $

    2,272,761

     

    IMVEXXY

     

     

    5,085,190

     

     

    3,121,711

     

     

    6,392,601

     

    BIJUVA

     

     

    1,352,001

     

     

    134,282

     

     

    1,111,604

     

    Prenatal vitamins

     

     

    2,428,382

     

     

    2,822,872

     

     

    2,473,691

     

    Net revenue

     

    $

    10,701,033

     

    $

    6,078,865

     

    $

    12,250,657

     

    Net product revenue for the second quarter of 2020 was affected by the COVID-19 pandemic across all of our products.

    Cost of Goods Sold/Gross Margin

    Cost of goods sold increased $1.7 million for the second quarter of 2020 compared to the first quarter of 2020, as the result of a non-cash write-off of $1.9 million primarily related to BIJUVA inventory obsolescence, partially offset by the impact of an overall decline in unit sales. The charge is the result of the Company's reprioritization of selling resources to ANNOVERA and IMVEXXY along with the impact of the COVID-19 pandemic on sales forecasts of BIJUVA for future quarters. This charge caused gross margin percentage to decline from 78% for the quarter ended March 31, 2020 to 59% for the quarter ended June 30, 2020.

    Expense, EPS and Related Information

    Total operating expenses decreased by $9.2 million to $51.3 million for the second quarter of 2020 as compared to $60.5 million for the first quarter of 2020. The decrease in operating expenses was primarily a result of the Company's cost containment and spend-rebalancing efforts to reduce overall spend in the remaining quarters of the 2020 fiscal year. For the remainder of 2020, spend will focus on delivering the necessary resources to support the launch of ANNOVERA, continued ramp-up of IMVEXXY, and ongoing brand management of BIJUVA. The second quarter of 2020 was impacted by $3.9 million in charges related to product samples expense as a result of the Company's decision to reduce sampling of BIJUVA.

    Net loss for the quarter ended June 30, 2020 decreased to $52.0 million, or $0.19 per basic and diluted share, compared with $56.8 million, or $0.21 per basic and diluted share, for the quarter ended March 31, 2020. Net loss per share for the second quarter of 2020 was impacted by inventory and sample expense charges related primarily to BIJUVA of $0.02 per basic and diluted share.

    Balance Sheet

    As of June 30, 2020, the Company's cash on hand totaled $113.8 million, compared with $170.1 million on March 31, 2020. The decline in cash was due primarily to the net loss for the quarter ended June 30, 2020, less certain non-cash items, as well as the timing of advertising, marketing, and social media campaigns for ANNOVERA that were incurred at the end of the quarter ended March 31, 2020 and funded early in the quarter ended June 30, 2020. Total outstanding debt, net of issuance costs, was $243.8 million as of June 30, 2020, compared to $243.4 million as of March 31, 2020. The change is due to the amortization of debt discount of $400,000.

    Sixth Street Additional Information

    • In connection with the adjustment to the Sixth Street total minimum net revenue covenant and in lieu of a cash amendment fee, the Company issued to the Sixth Street lenders warrants to purchase an aggregate of approximately 4.75 million shares of the Company's common stock with an exercise price of $1.58 per share and a ten year term. The warrants are unregistered, do not have registration rights, and do not have anti-dilution protection, other than for customary stock splits and similar transactions.
    • The total minimum net revenue requirement for ANNOVERA, IMVEXXY, and BIJUVA in 2022 will be $65 million, $75 million, $85 million, and $95 million for the first, second, third, and fourth quarters, respectively, and will remain at $95 million for subsequent quarters.

    Conference Call and Webcast Details

    TherapeuticsMD will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss these financial results and provide a business update.

    Date:

    Thursday, August 6, 2020

    Time:

    8:30 a.m. ET

    Telephone Access (US):

    866-665-9531

    Telephone Access (International):

    724-987-6977

    Access Code for All Callers:

    2963048

    A live webcast and audio archive for the event may be accessed on the home page or from the "Investors & Media" section of the TherapeuticsMD website at www.therapeuticsmd.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call's completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 2963048.

    Please see the Full Prescribing Information, including indication and Boxed WARNING, for each TherapeuticsMD product as follows:

    About TherapeuticsMD

    TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

    Forward-Looking Statements

    This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD's objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company's ability to maintain or increase sales of its products; the company's ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company's current or future approved products or preclude the approval of the company's future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company's ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company's reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company's licensees to commercialize and distribute the company's products; the ability of the company's marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company's products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company's common stock and the concentration of power in its stock ownership. PDF copies of the company's historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.

     
    THERAPEUTICSMD, INC. AND SUBSIDIARIES
    CONSOLIDATED BALANCE SHEETS
     

    June 30, 2020

    December 31, 2019
    (Unaudited)
     
    ASSETS
    Current Assets:
    Cash

    $

    113,839,234

    $

    160,829,713

    Accounts receivable, net of allowance for doubtful accounts of $722,240 and $904,040, respectively

    18,290,784

    24,395,958

    Inventory, net

     

    10,172,312

     

    11,860,716

    Other current assets

     

    6,641,587

     

    11,329,793

    Total current assets

     

    148,943,917

     

    208,416,180

     
    Fixed assets, net

     

    2,145,926

     

    2,507,775

     
    Other Assets:
    License rights, net

     

    37,721,695

     

    39,221,308

    Intangible assets, net

     

    5,942,873

     

    5,258,211

    Right of use assets

     

    10,337,577

     

    10,109,154

    Other assets

     

    446,925

     

    473,009

    Total other assets

     

    54,449,070

     

    55,061,682

    Total assets

    $

    205,538,913

    $

    265,985,637

     
    LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
    Current Liabilities:
    Accounts payable

    $

    17,270,319

    $

    19,181,212

    Other current liabilities

     

    29,213,411

     

    33,823,613

    Total current liabilities

     

    46,483,730

     

    53,004,825

     
    Long-Term Liabilities:
    Long-term debt

     

    243,801,705

     

    194,634,643

    Operating lease liability

     

    9,307,361

     

    9,145,049

    Other long-term liabilities

     

    35,000

     

    -

    Total long-term liabilities

     

    253,144,066

     

    203,779,692

    Total liabilities

     

    299,627,796

     

    256,784,517

     
     
    Commitments and Contingencies
     
    Stockholders' (Deficit) Equity:
    Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding - -
    Common stock - par value $0.001; 600,000,000 and 350,000,000 shares authorized; 272,294,380 and 271,177,076 issued and outstanding, respectively

    272,294

    271,177

    Additional paid-in capital

     

    709,885,568

     

    704,351,222

    Accumulated deficit

     

    (804,246,745)

     

    (695,421,279)

    Total stockholders' (deficit) equity

     

    (94,088,883)

     

    9,201,120

    Total liabilities and stockholders' equity

    $

    205,538,913

    $

    265,985,637

     
    THERAPEUTICSMD, INC. AND SUBSIDIARIES
    CONSOLIDATED STATEMENTS OF OPERATIONS
    (Unaudited)
     
    Three Months Ended Three Months Ended Six Months Ended
    June 30, March 31, June 30,

    2020

    2019

    2020

    2020

    2019

     
     
    Product revenue, net

    $

    10,701,033

    $

    6,078,865

    $

    12,250,657

    $

    22,951,690

    $

    10,025,516

     
    Cost of goods sold

     

    4,400,485

     

    1,248,860

     

    2,715,051

     

    7,115,536

     

    2,011,687

     
    Gross profit

     

    6,300,548

     

    4,830,005

     

    9,535,606

     

    15,836,154

     

    8,013,829

     
    Operating expenses:
    Sales, general, and administrative

     

    48,340,628

     

    41,387,451

     

    56,927,021

     

    105,267,649

     

    76,251,533

    Research and development

     

    2,742,032

     

    4,964,368

     

    3,268,829

     

    6,010,861

     

    11,282,250

    Depreciation and amortization

     

    256,557

     

    115,059

     

    261,994

     

    518,551

     

    221,997

    Total operating expenses

     

    51,339,217

     

    46,466,878

     

    60,457,844

     

    111,797,061

     

    87,755,780

     
    Operating loss

     

    (45,038,669)

     

    (41,636,873)

     

    (50,922,238)

     

    (95,960,907)

     

    (79,741,951)

     
    Other (expense) income
    Loss on extinguishment of debt

     

    -

     

    (10,057,632)

     

    -

     

    -

     

    (10,057,632)

    Miscellaneous income

     

    88,858

     

    486,597

     

    335,482

     

    424,340

     

    1,175,318

    Interest expense

     

    (7,026,853)

     

    (4,028,609)

     

    (6,262,046)

     

    (13,288,899)

     

    (6,118,627)

    Total other expense

     

    (6,937,995)

     

    (13,599,644)

     

    (5,926,564)

     

    (12,864,559)

     

    (15,000,941)

     
    Loss before income taxes

     

    (51,976,664)

     

    (55,236,517)

     

    (56,848,802)

     

    (108,825,466)

     

    (94,742,892)

     
    Provision for income taxes

     

    -

     

    -

     

    -

     

    -

     

    -

     
    Net loss

    $

    (51,976,664)

    $

    (55,236,517)

    $

    (56,848,802)

    $

    (108,825,466)

    $

    (94,742,892)

     
    Loss per share, basic and diluted:
     
    Net loss per share, basic and diluted

    $

    (0.19)

    $

    (0.23)

    $

    (0.21)

    $

    (0.40)

    $

    (0.39)

     
    Weighted average number of common shares outstanding, basic and diluted

    271,876,238

    241,221,840

    271,459,522

    271,667,879

    241,114,532

     
    THERAPEUTICSMD, INC. AND SUBSIDIARIES
    CONSOLIDATED STATEMENTS OF CASH FLOWS
    (Unaudited)
     
    Six Months Ended
    June 30,

    2020

    2019

     
    CASH FLOWS FROM OPERATING ACTIVITIES
    Net loss

    $

    (108,825,466)

    $

    (94,742,892)

    Adjustments to reconcile net loss to net cash used in operating activities:
    Depreciation of fixed assets

     

    387,649

     

    133,049

    Amortization of intangible assets

     

    130,902

     

    88,948

    Write off of patent and trademark costs

     

    -

     

    78,864

    Operating lease impairment

     

    81,309

     

    -

    Non-cash operating lease expense

     

    689,089

     

    443,734

    (Recovery of) provision for doubtful accounts

     

    (181,800)

     

    167,500

    Inventory obsolesence reserve

     

    5,965,139

     

    -

    Loss on extinguishment of debt

     

    -

     

    10,057,632

    Share-based compensation

     

    5,369,279

     

    5,224,212

    Amortization of deferred financing fees

     

    692,442

     

    316,880

    Amortization of license fee

     

    1,499,613

     

    -

    Changes in operating assets and liabilities:
    Accounts receivable

     

    6,286,974

     

    (7,486,691)

    Inventory

     

    (4,276,735)

     

    (4,226,770)

    Other current assets

     

    4,412,827

     

    1,710,697

    Accounts payable

     

    (1,910,893)

     

    (3,244,603)

    Accrued expenses and other current liabilities

     

    (5,420,628)

     

    2,801,717

     
     
    Net cash used in operating activities

     

    (95,100,299)

     

    (88,677,723)

     
    CASH FLOWS FROM INVESTING ACTIVITIES
    Patent costs

     

    (815,564)

     

    (763,247)

    Purchase of fixed assets

     

    (25,800)

     

    (1,092,504)

    Security deposit

     

    35,000

     

    (20,420)

     
    Net cash used in investing activities

     

    (806,364)

     

    (1,876,171)

     
    CASH FLOWS FROM FINANCING ACTIVITIES
    Proceeds from exercise of options and warrants

     

    166,184

     

    100,107

    Repayment of the Credit Agreement

     

    -

     

    (81,660,719)

    Proceeds from the Financing Agreement

     

    50,000,000

     

    200,000,000

    Payment of deferred financing fees

     

    (1,250,000)

     

    (6,652,270)

     
    Net cash provided by financing activities

     

    48,916,184

     

    111,787,118

     
    Increase (decrease) in cash

     

    (46,990,479)

     

    21,233,224

    Cash, beginning of period

     

    160,829,713

     

    161,613,077

    Cash, end of period

    $

    113,839,234

    $

    182,846,301

     
    Supplemental disclosure of cash flow information
     
    Interest paid

    $

    12,032,014

    $

    6,989,570

     

    View Full Article Hide Full Article
View All TherapeuticsMD Inc. News